An interventional study of Plasma Exchange and 5% human albumin in Frailty and Plasma Exchange, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Frailty with a site in China — 25 open to participants now, 27 under way, none of them phase 3. Frailty · China.
Among the 64 studies in Frailty with a site in China, this one is the 28th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2026, is one of 25 with no phase, reaches primary completion later than 21 of the 26 other live ones, and was the 60th registered.
1,286 studies on the registry are indexed under Frailty; 454 are open to participants now.
Browse Frailty studies →25 of the 64 studies in Frailty with a site in China are open now. Recruiting first, the newest first:
Guangdong Provincial People's Hospital · Sites in China
Ages 75+
Jiawei Jiang · Sites in China
Ages 60–85
Huashan Hospital · Sites in China
Ages 61+
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18+ · Healthy volunteers
Lanyue Zhu · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 301 Frailty studies recruiting now, 236 (78%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 67 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 1 · Phase 4 2
First in 2013; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34 is below the median of 82 across 769 interventional studies indexed under Frailty.
Median enrollment 164 across the 31 interventional studies, 500 across the 33 observational. Of the 27 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 64 has an industry lead sponsor. The 10 most frequent:
Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 413 studies on the registry; 291 are open to participants now.
Institute of Hematology & Blood Diseases Hospital, China has 1 study filed under Frailty — fewer than ten, so there is no comparison to draw.
7 of the studies in Frailty with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05635877Yongtao SunEffects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients | 2026-11-30 |
| NCT06765499First People's Hospital of HangzhouThe Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease | 2026-12-30 |
| NCT07845656Jiawei JiangA Home-based Multicomponent Exercise Intervention Program Based on the Fogg Behavior Model (FBM) for Older Adults With Osteosarcopenia and Frailty | 2026-12-31 |
| NCT07030179Lanyue ZhuThe Relationship Between Preoperative Frailty and Postoperative AKI and the Mediating Effect of Intraoperative BP | 2026-12-31 |
| NCT05598112Chinese Academy of Medical Sciences, Fuwai HospitalEffect of Gut Microbiome Intervention on Aging Via Oral FMT | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 64 studies in Frailty with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background Frailty is an age-related syndrome characterized by reduced physiological reserve, decreased stress tolerance and multisystem functional decline in the elderly, which markedly increases the risks of falls, hospitalization, functional impairment and all-cause mortality. Chronic low-grade inflammation, immune senescence, oxidative stress and abnormal protein modification are key mechanisms underlying the development and progression of frailty. Current mainstream interventions including nutritional support and physical exercise yield limited efficacy for moderate to severe frailty, and targeted therapies against biological aging mechanisms are still lacking.Objective To evaluate the efficacy and safety of plasma exchange combined with human albumin (ALB), with or without intravenous immunoglobulin (IVIg), in the treatment of frailty, and to preliminarily explore the potential mechanisms of the combined therapy.Methods This is a prospective, randomized, exploratory clinical trial. A total of 34 participants with a FRAIL scale score ≥ 1 will be enrolled and randomly assigned at a 1:1 ratio into two groups, with 17 cases in each group: the plasma exchange plus ALB group and the plasma exchange plus ALB plus IVIg group. The study consists of a screening phase, a 5-month treatment phase with six intervention sessions, and follow-up visits at 1, 3 and 6 months after the final treatment. Frailty status, physical function, laboratory parameters, inflammatory levels and albumin modification will be dynamically assessed throughout the trial, and adverse events will be recorded.Results The trial has not yet been initiated. It is expected that the within-group and between-group comparisons will clarify the therapeutic effects and long-term stability of the two regimens, as well as their safety profiles. Changes in biomarkers will help illustrate the potential molecular mechanisms of plasma purification combined with functional protein supplementation for frailty.Conclusion Plasma exchange combined with ALB (with or without IVIg) can exert multi-target intervention on frailty by eliminating aging-related toxic factors and restoring plasma and immune homeostasis. The findings of this study will provide preliminary clinical evidence and theoretical basis for novel biological therapeutic strategies for frailty.
Frailty is a common age-related clinical syndrome characterized by progressive decline in physiological reserve, reduced stress tolerance, and multisystem functional impairment in older adults. It significantly increases the risk of adverse outcomes including falls, hospitalizations, functional dependence, and all-cause mortality. Chronic low-grade inflammation, immune senescence, oxidative stress, and abnormal protein modification are considered key biological mechanisms driving the onset and progression of frailty. Current mainstream interventions, such as nutritional support and physical exercise, have shown only limited efficacy in moderate to severe frailty, and targeted biological therapies for frailty remain lacking. This study aims to evaluate the efficacy and safety of plasma exchange combined with human albumin (ALB), with or without adjunctive intravenous immunoglobulin (IVIg), in the treatment of frailty, and to preliminarily explore the potential mechanisms underlying the combined therapy.
This is a prospective, randomized, exploratory clinical trial. A total of 34 participants with a FRAIL scale score of ≥ 1 will be enrolled and randomly assigned at a 1:1 ratio into two groups (17 participants in each group): the plasma exchange plus human albumin group (ALB group) and the plasma exchange plus human albumin plus intravenous immunoglobulin group (ALB + IVIg group). The study is divided into three phases: a screening phase, a treatment phase, and a follow-up phase.
The screening phase will be conducted within 7 days prior to the first treatment. Eligible subjects will sign an informed consent form and complete a comprehensive baseline assessment, including frailty status evaluation, physical function testing, routine laboratory and imaging examinations, frailty-related biomarker detection, albumin (ALB) modification profiling, and inflammatory marker testing to confirm eligibility.
The treatment phase will last for 5 months, consisting of a total of 6 treatment sessions administered monthly. Systemic assessments will be performed at each visit, including frailty status evaluation, physical function testing, routine pre-treatment examinations, frailty-related biomarker detection, ALB modification profiling, and inflammatory marker testing, to monitor treatment response and safety. Blood samples for complete blood count and coagulation function will be collected within 1 hour after the first plasma exchange session. All participants will receive plasma exchange with 5% human albumin solution as the replacement fluid, according to the study protocol. Subjects in the ALB + IVIg group will additionally receive intravenous immunoglobulin (IVIg) immediately after each plasma exchange session. Adverse events will be recorded throughout the study.
Follow-up visits will be conducted at 1, 3, and 6 months after the final treatment session. All assessments and laboratory tests will be repeated to evaluate the long-term efficacy, safety, and sustained effects of the interventions.
This trial has not yet been initiated. It is expected that within-group and between-group comparisons will clarify the therapeutic effects and long-term stability of the two regimens, as well as their safety profiles. Changes in frailty-related biomarkers, inflammatory markers, and albumin modification patterns will help to illustrate the potential molecular mechanisms of plasma exchange combined with functional protein supplementation for frailty. It is hypothesized that plasma exchange combined with ALB (with or without IVIg) may exert multi-targeted intervention on frailty by eliminating aging-related toxic factors and restoring plasma and immune homeostasis. The findings of this study will provide preliminary clinical evidence and a theoretical basis for novel biological therapeutic strategies for frailty.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects receive standard background therapy. Subjects receive monthly plasma exchange for 6 cycles with 5% human albumin as replacement fluid, no IVIg administration.
Procedure: Plasma Exchange · Biological: 5% human albumin
All subjects receive standard background therapy. Subjects receive monthly plasma exchange for 6 cycles with 5% human albumin replacement fluid, plus IVIg 2.5 g after each exchange session.
Procedure: Plasma Exchange · Biological: 5% human albumin · Biological: Intravenous immunoglobulin (IVIG)
Plasma exchange procedure, target exchange volume 50±5 mL/kg per session, flow rate 40-60 mL/min, administered once monthly for 6 cycles.
Equal-volume 5% human albumin solution used as replacement fluid during plasma exchange.
IVIg administered at a fixed dose of 2.5 g per subject, infused immediately after each plasma exchange session.
Efficacy rate of frailty intervention at 1 month after the last treatment
Calculation formula: \[(Baseline score - Follow-up score at 1 month after the last treatment) / Baseline score\] × 100%. This rate represents the degree of improvement in patients' frailty status following intervention.
Time frame: 1 month after the last treatment
Efficacy rate of frailty intervention assessed by FRAIL Scale
The efficacy rate of frailty intervention calculated based on the FRAIL Scale (Fatigue, Resistance, Ambulation, Illnesses, Loss of weight). The scale ranges from 0 (no frailty) to 5 (severe frailty); higher scores indicate worse frailty status. Efficacy rate = (Baseline score - Score at follow-up) / Baseline score × 100%.
Time frame: Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment
Strand specificity of frailty-related cfDNA and therapeutic response to plasma exchange
Assess strand specificity of frailty-related circulating cell-free DNA and evaluate its predictive value for plasma exchange treatment response.
Time frame: Baseline, 1 month and 6 months after the last treatment
Clonal hematopoiesis gene mutation dynamics and correlation with frailty
Observe clonal hematopoiesis-associated gene mutation and clonal evolution at baseline, 1 month and 6 months post last treatment; explore the correlation between clonal hematopoiesis features and frailty status.
Time frame: Baseline, 4 week,24 week, 28 week, and 32 week after enrollment
BCR clonotype characteristics
Analysis of BCR clonotype derived from identical BCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.
Time frame: Baseline, 1 month and 6 months after the last treatment
BCR V/J gene usage bias
Analysis of BCR V/J gene usage bias derived from identical BCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.
Time frame: Baseline, 1 month and 6 months after the last treatment
BCR diversity index
Analysis of BCR diversity index derived from identical BCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.
Time frame: Baseline, 1 month and 6 months after the last treatment
Frequency of senescence-associated antigen-specific B cell clones
Analysis of senescence-associated antigen-specific B cell clones derived from identical BCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.
Time frame: Baseline, 1 month and 6 months after the last treatment
TCR clonotype characteristics
Analysis of TCR clonotype derived from a single unified TCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.
Time frame: Baseline, 1 month and 6 months after the last treatment
TCR diversity index
Analysis of TCR diversity index derived from a single unified TCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.
Time frame: Baseline, 1 month and 6 months after the last treatment
TCR V/J gene usage bias
Analysis of TCR V/J gene usage bias derived from a single unified TCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.
Time frame: Baseline, 1 month and 6 months after the last treatment
Frequency of senescence-associated antigen-specific T cell clones
Analysis of senescence-associated antigen-specific T cell clones derived from a single unified TCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.
Time frame: Baseline, 1 month and 6 months after the last treatment
Between-group differences in frailty scale score: ALB group vs ALB+IVIg group
Compare the changes of frailty scale score between albumin monotherapy group and albumin combined with IVIg group.
Time frame: Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment
Baseline changes of serum ALB modification at 1 month after last treatment
Evaluate the alterations of serum albumin subtypes including oxidation, glycation, nitration, sulfenylation, cysteinylation, cysteinylation combined with glycation versus baseline.
Time frame: 1 month after the last treatment
Changes from baseline in senescence-related indicators at 1 month after last treatment
Detect plasma proteome and glycoproteome related to senescence, including SASP, serum inflammatory factors and epigenetic senescence clock, and analyze their changes compared with baseline.
Time frame: 1 month after the last treatment
Changes from baseline in Tilburg Frailty Indicator (TFI) scores
To evaluate the changes of Tilburg Frailty Indicator (TFI) score compared with baseline at each follow-up time point.
Time frame: Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment
Changes from baseline in Fried Frailty Phenotype Scale scores
To evaluate the change of Fried Frailty Phenotype Scale score compared with baseline. This is one single outcome indicator (scale score) assessed repeatedly at multiple planned follow-up time points, not multiple distinct outcome measures.This represents one continuous outcome (Frailty Phenotype score) assessed longitudinally at multiple prespecified time points.
Time frame: Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment
Changes from baseline in physical and mental health questionnaire scores
Assess changes from baseline in EQ-5D, PROMIS-29, Generalized Anxiety Disorder (GAD) scale, Patient Health Questionnaire (PHQ), Pittsburgh Sleep Quality Index (PSQI).
Time frame: Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment
Short Physical Performance Battery (SPPB) score
To evaluate patients' physical function using the Short Physical Performance Battery (SPPB). This single continuous scale outcome will be repeatedly assessed at multiple scheduled follow-up time points.
Time frame: Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment
Changes in gene mutation frequency and its correlation with immune cell subsets
Analyze the shift of gene mutation frequency before and after treatment, and explore the correlation between mutation frequency and immune cell profiles.
Time frame: Baseline, 1 month and 6 months after the last treatment
Changes from baseline in CRP
Detect serum CRP, and calculate their changes compared with baseline at predefined visits.
Time frame: Baseline, 4 week, 24 week, 28 week, and 32 week after enrollment
Changes from baseline in ESR levels
Detect serum erythrocyte sedimentation rate (ESR) , and calculate their changes compared with baseline at predefined visits.
Time frame: Baseline, 4 week, 24 week, 28 week, and 32 week after enrollment
Changes from baseline in ferritin levels
To assess changes in serum ferritin concentration relative to baseline.
Time frame: Baseline, 4 week, 24 week, 28 week, and 32 week after enrollment
Incidence of adverse events during treatment
The incidence rate of all adverse events occurring during the treatment period will be calculated. Focused adverse events include catheter-related infections, hypersensitivity reactions, thrombosis, and other related adverse events.
Time frame: From initiation of the first treatment through 6-month after completion of all study treatments, assessed up to 12 months
Start is estimated for Sep 2026; primary completion for May 2028, 19 months later.
Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 19 months is below that.
Counting every sponsor, half of 518 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumins human
Institute of Hematology & Blood Diseases Hospital, China →